Insulin resistance and progression to Type 1 Diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT)

PJ Bingley, JL Mahon, EAM Gale, Group The European Nicotinamide Diabetes Intervention Trial (ENDIT)

Research output: Contribution to journalArticle (Academic Journal)peer-review

75 Citations (Scopus)

Abstract

ABSTRACT Objective: Insulin resistance can modulate progression to type 1 diabetes in individuals with ongoing islet autoimmunity. We wanted to see whether measures of insulin resistance improved risk assessment in ICA positive relatives when added to other immune and metabolic markers. Research Design and Methods: The retrospective cohort analysis included 213 family members participating in the European Nicotinamide Diabetes Intervention Trial. All were aged less than 25, with at least one islet antibody in addition to ICA ≥ 20 JDF units. Median length of follow-up was 4.21 years and 105 individuals developed diabetes. Oral and intravenous glucose tolerance tests were performed at baseline, antibodies to GAD, IA-2 and insulin determined by radioimmunoassay, and insulin resistance estimated by homeostatic model assessment. Risk was assessed by Cox regression analysis Results: The overall cumulative risk of diabetes within 5 years was 54.1% (95% CI 46.0-62.3). Multivariate analysis confirmed that baseline FPIR quartile (p
Translated title of the contributionInsulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT)
Original languageEnglish
Pages (from-to)146 - 150
Number of pages5
JournalDiabetes Care
Volume31
Issue number1
DOIs
Publication statusPublished - Jan 2008

Fingerprint Dive into the research topics of 'Insulin resistance and progression to Type 1 Diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT)'. Together they form a unique fingerprint.

Cite this